CXCL13 CSF level inversely correlates with duration of disease in primary progressive multiple sclerosis

Jacek Losy; Piotr Iwanowski; Elżbieta Kaufman; Marlena Wójcicka

doi:10.20883/jms.2016.169

Authors

Jacek Losy Department of Clinical Neuroimmunology, Chair of Neurology, Poznan University of Medical Sciences, Poland Department of Neurology,Chair of Neurology, Poznan University of Medical Sciences, Poland
Piotr Iwanowski Department of Clinical Neuroimmunology, Chair of Neurology, Poznan University of Medical Sciences, Poland Department of Neurology,Chair of Neurology, Poznan University of Medical Sciences, Poland
Elżbieta Kaufman Department of Clinical Neuroimmunology, Chair of Neurology, Poznan University of Medical Sciences, Poland
Marlena Wójcicka Department of Clinical Neuroimmunology, Chair of Neurology, Poznan University of Medical Sciences, Poland

DOI:

https://doi.org/10.20883/jms.2016.169

Keywords:

chemokines, multiple sclerosis, immunopathology

Abstract

Chemokines are important factors in the immunopathogenesis of multiple sclerosis. The objective of the study was to examine the CSF and serum levels of CXCL13 and CCL5 chemokines in primary progressive MS, compare results with relapsing remitting MS and control group with other noninflammatory neurological disorders. The levels of chemokines was measured by ELISA method. The CXCL13 CSF levels in PP and RR MS were higher in comparison with control group, without significant differences between these podgroups. Additionally CXCL13 level in PP MS inversely correlated with duration of the disease. CCL5 CSF level was also significantly higher in PP MS in comparison with control group. The results demonstrate involvement of CXCL13 and CCL5 chemokines in the immunopathogenetic mechanisms of primary progressive MS.

Downloads

Download data is not yet available.

References

Iwanowski P, Losy J. Immunological differences between classical phenotypes of multiple sclerosis. J Neurol Scie. 2015,349:10–14.

Miller DH, Leary SM. Primary progressive multiple sclerosis. Lancet Neurol. 2007;6:903–912.

Sellebjerg F, Börnsen L, Khademi M, Krakauer MOT, Fredriksen JL, Sorensen PS. Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS. Neurology. 2009;73:2003–2010.

Sorensen TL, Tani M, Jensen J, Pierce V, Lucchinetti C, Folcik VA et al. Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J Clin Invest. 1999;103:807–815.

Polman Ch.H, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to McDonald criteria. Ann Neurol. 2011;69:292–302.

Gun MD, Ngo WN, Ansel KM, Ekland EH, Cyster JC, Williams LT. B-cell-homing chemokine made in lymphoid follicles activates Burkitt's lymphoma receptor-1. Nature. 1998;391:799–803.

Krumbholtz M, Theil D, Cepok S, Hemmer B, Kivisäkk P, Ransohoff RM et al. Chemokines in multiple sclerosis: CXCCL12 and CXCL13 up-regulation is differently linked to CNS immune cell recruitment. Brain. 2006;129:200–211.

Mahad DJ, Howell SJL, Woodroofe MN. Expression of chemokines in the CSF and correlation with clinical disease activity in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry. 2002;72:498–502.